| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash | 724,502 | 1,338,222 | ||
| Prepaid and other current assets | 478,868 | 444,086 | ||
| Total current assets | 1,203,370 | 1,782,308 | ||
| Due from related party, non-current | 126,275 | 126,275 | ||
| Property and equipment, net | 12,764 | 198 | ||
| Total non-current assets | 139,039 | 126,473 | ||
| Total assets | 1,342,409 | 1,908,781 | ||
| Accounts payable and accrued expenses | 559,171 | 431,873 | ||
| Accrued interest, related parties | 184,869 | 165,817 | ||
| Due to related parties-Related Party | 178,053 | 170,553 | ||
| Short-term debt, related parties | 1,442,500 | 1,442,500 | ||
| Deferred underwriting fee payable | 500,000 | 500,000 | ||
| Deferred underwriting fee - common stock payable | - | 7,805,000 | ||
| Total current liabilities | 2,864,593 | 10,515,743 | ||
| Warrant liability | 123,579 | 200,450 | ||
| Total liabilities | 2,988,172 | 10,716,193 | ||
| Common stock, 0.0001 par value 500,000,000 shares authorized 27,064,633 and 17,500,000 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 2,706 | 2,601 | ||
| Additional paid-in capital | 29,054,337 | 20,069,442 | ||
| Accumulated deficit | -30,702,806 | -28,879,455 | ||
| Total stockholders' deficit | -1,645,763 | -8,807,412 | ||
| Total liabilities and stockholders' deficit | 1,342,409 | 1,908,781 | ||
Liminatus Pharma, Inc. (LIMN)
Liminatus Pharma, Inc. (LIMN)